SCHEMBL210959

SCHEMBL210959

CCCNC(=O)c1ccc(-c2cc(Cl)c(CC3CCN(C4CCCCC4)C3=O)c(Cl)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.42
MAPK14 Q16539 1/20 0.39
HPGD P15428 2/20 0.38
DRD2 P14416 2/20 0.38
DRD4 P21917 2/20 0.38
DRD3 P35462 2/20 0.38
PDE1A P54750 2/20 0.38
PDE1B Q01064 2/20 0.38
PDE4D Q08499 2/20 0.38
PDE7A Q13946 2/20 0.38
PDE1C Q14123 2/20 0.38
PDE3A Q14432 2/20 0.38
TP53 P04637 2/20 0.37
MAPT P10636 2/20 0.37
MCHR1 Q99705 2/20 0.37
BMPR1B O00238 1/20 0.37
BMPR1A P36894 1/20 0.37
TGFBR1 P36897 1/20 0.37
ACVRL1 P37023 1/20 0.37
ACVR1 Q04771 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL210257 0.93 HSD11B1 (0.43) HSD11B1MAPK14PDE7ATP53MAPT
SCHEMBL209301 0.91 HSD11B1 (0.42) HSD11B1PDE1APDE1BPDE4DPDE7A
SCHEMBL208204 0.90 PDE4D (0.49) HSD11B1HPGDPDE1APDE1BPDE4D
SCHEMBL2720661 0.89 HRH3 (0.48) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL209754 0.89 HSD11B1 (0.45) HSD11B1PDE7AMAPTMEN1KMT2A
SCHEMBL209956 0.88 HSD11B1 (0.45) HSD11B1PDE4DPDE4B
SCHEMBL211427 0.88 HSD11B1 (0.44) HSD11B1MAPK14HPGDTP53BMPR1B
SCHEMBL2722387 0.88 CNR2 (0.46) HSD11B1HPGDTP53KMT2A
SCHEMBL209985 0.87 CNR2 (0.45) HSD11B1HPGDTP53BMPR1BBMPR1A
SCHEMBL210958 0.87 HRH3 (0.44) HSD11B1MAPK14MEN1KMT2APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2016047-B1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-08-28 EP claimed
US-8088776-B2 Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-01-03 US claimed
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-06-18 US claimed
EP-2016047-B1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885MAPK14 1613/4885HPGD 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.